Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply

Affiliations

¹ Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai, China.
² Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas.

Editorial

Hong Lu et al. Aliment Pharmacol Ther. 2019 Aug.

. 2019 Aug;50(3):332.

doi: 10.1111/apt.15373.

¹ Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai, China.
² Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas.

No abstract available

Comment on

Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H. Chen Q, et al. Aliment Pharmacol Ther. 2019 Jun;49(11):1385-1394. doi: 10.1111/apt.15273. Epub 2019 Apr 24. Aliment Pharmacol Ther. 2019. PMID: 31020673 Clinical Trial.
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment.
Argueta EA, Moss SF. Argueta EA, et al. Aliment Pharmacol Ther. 2019 Aug;50(3):331-332. doi: 10.1111/apt.15302. Aliment Pharmacol Ther. 2019. PMID: 31313363 No abstract available.